Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Umbilical Cord Mesenchymal Stem Cells vs Low-dose IL-2 in Lupus Nephritis
NCT05631717Phase 3Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Oct 2022
- Primary completion
- Jun 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of human umbilical cord mesenchymal stem cells in lupus nephritis (LN) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Response rates (Complete Response and Renal Response) at 24 weeks. Started Oct 2022; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05631717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631717.